Abstract | OBJECTIVE: METHODS: Clinical data of 102 de novo AML patients who received primary anti-IPA prophylaxis during the first induction chemotherapy were analyzed retrospectively. All the cases were divided into voriconazole-treated group and posaconazole-treated group according to the prophylactic agent. The incidences of IPA and systemic antifungal treatment during induction chemotherapy were analyzed for both groups. RESULTS: Among 102 enrolled cases, 42 cases received voriconazole and other 60 received posaconazole as primary prophylaxis. IPA occurred in 3 cases of voriconazole group (1 probable, 2 possible); IPA occurred in 4 cases of posaconazose group, and all were possible cases. The incidence of IPA during remission-induction chemotherapy in variconazole group equaled to posaconazose group (7.1% vs. 6.7%) (P=0.925). Beside IPA cases, 2 cases in voriconazole group and 4 cases in posaconazole group received intravenous anti aspergillosis drugs preemptive treatment, and no significant difference of prophylactic success rate was observed between two groups (88.1% vs. 86.7%) (P=0.831). Visual disturbance was the most common adverse event occurred in voriconazole group, but no significant differences of incidences of other adverse effects were observed when compared with posaconazole group. CONCLUSION:
|
Authors | Ben-Fa Gong, Dong Lin, Hui Wei, Ying Wang, Bing-Cheng Liu, Chun-Lin Zhou, Kai-Qi Liu, Shu-Ning Wei, Guang-Ji Zhang, Yun-Tao Liu, Xiao-Yuan Gong, Yan Li, Xing-Li Zhao, Shao-Wei Qiu, Run-Xia Gu, Ying-Chang Mi, Jian-Xiang Wang |
Journal | Zhongguo shi yan xue ye xue za zhi
(Zhongguo Shi Yan Xue Ye Xue Za Zhi)
Vol. 26
Issue 5
Pg. 1269-1274
(Oct 2018)
ISSN: 1009-2137 [Print] China |
PMID | 30295237
(Publication Type: Journal Article)
|
Chemical References |
- Antifungal Agents
- Voriconazole
|
Topics |
- Antifungal Agents
- Humans
- Induction Chemotherapy
- Leukemia, Myeloid, Acute
- Mycoses
- Pulmonary Aspergillosis
- Retrospective Studies
- Voriconazole
|